Comparing two PET scans for diagnosing medullary thyroid carcinoma
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma: a Prospective Study
This study is testing which of two types of PET scans works better for diagnosing and staging medullary thyroid carcinoma in patients who might have this cancer.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06520319 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of 68Ga-MGS5 PET/CT compared to 68Ga-DOTATATE PET/CT in diagnosing and staging medullary thyroid carcinoma (MTC). It will enroll 20 patients with suspected MTC or MTC recurrence, who will undergo both types of PET/CT scans within a week. The study will also assess the expression of CCK2 receptors in tumor samples to correlate with imaging results. The goal is to determine which imaging method provides better diagnostic accuracy for MTC.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 with confirmed medullary thyroid carcinoma or suspected recurrence.
Not a fit: Patients who are pregnant, breastfeeding, or have claustrophobia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for medullary thyroid carcinoma, enhancing patient management and outcomes.
How similar studies have performed: While there have been studies on PET imaging for various cancers, the specific comparison of 68Ga-MGS5 and 68Ga-DOTATATE in MTC is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of either gender, aged ≥ 18 years and ≤80 years. * Patients with pathologic findings confirming the diagnosis of MTC * Patients with MTC recurrence * Signed written consent Exclusion Criteria: * Pregnant or breastfeeding female patients * Patients with claustrophobic behavior * The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Principal investigator: Weibing Miao — First Affiliated Hospital of Fujian Medical University
- Study coordinator: Weibing Miao
- Email: miaoweibing@126.com
- Phone: 86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.